Information on CF

Basic details

Name: Cystic fibrosis | Acronym: CF
Alt. names:

Gene: CFTR | MOI: Autosomal recessive | Mechanism of action:

No. of cases in DB: 0 | First reported in: 1989

Last updated on: 2023-02-28 16:41:18 by

OMIM: 219700

Orphanet: 586

MONDO: -

DOID: -

ClinGen:

Description

It is a chronic and generally progressive disease. The initial symptoms are thick secretions and chronic infections in the lung, bulky diarrhea, and short stature. However, any internal organ can be affected, and the main manifestations occur in the respiratory system (chronic bronchitis), the pancreas (pancreatic insufficiency, adolescent diabetes and occasionally pancreatitis) and, more rarely, the intestine (stercoral obstruction) or the liver (cirrhosis). Male sterility is a common trait. Mortality and morbidity depend on the degree of bronchopulmonary involvement, and there are late and less severe forms of the disease.

Management

Current treatments, which are only symptomatic, include: bronchial drainage and antibiotics for respiratory infections; administration of vitamins and caloric supplements for digestive and nutritional problems; and insulin replacement for diabetes. Although these treatments have significantly improved the prognosis of patients, therapies that correct the biochemical defects are being studied. The new CFTR modulators partially restore chloride channel function in 90% of patients, although they are not yet effective for absent, truncated, or severely malformed proteins.

Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.

0 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Bronchiectasisarrow icon 106 (95.5%) 0 (0.0%) 5 (4.5%)
2 Elevated sweat chloridearrow icon 77 (99.9%) 0 (0.0%) 0 (0.0%)
3 Chronic sinusitisarrow icon 59 (52.7%) 0 (0.0%) 53 (47.3%)
4 Reduced forced expiratory volume in one secondarrow icon 26 (66.7%) 0 (0.0%) 13 (33.3%)
5 Salty tasting skinarrow icon 21 (42.9%) 0 (0.0%) 28 (57.1%)
6 Decreased forced expiratory flow 25-75%arrow icon 15 (71.4%) 0 (0.0%) 6 (28.6%)
7 Diarrheaarrow icon 15 (21.1%) 0 (0.0%) 56 (78.9%)
8 Exocrine pancreatic insufficiencyarrow icon 11 (40.7%) 0 (0.0%) 16 (59.3%)
9 Clubbing of fingersarrow icon 9 (42.9%) 0 (0.0%) 12 (57.1%)
10 Failure to thrivearrow icon 8 (38.1%) 0 (0.0%) 13 (61.9%)
11 Recurrent pneumoniaarrow icon 8 (38.1%) 0 (0.0%) 13 (61.9%)
12 Infantile onsetarrow icon 6 (85.7%) 0 (0.0%) 1 (14.3%)
13 Reduced forced vital capacityarrow icon 5 (23.8%) 0 (0.0%) 16 (76.2%)
14 hemoptysisarrow icon 3 (14.3%) 0 (0.0%) 18 (85.7%)
15 Ileusarrow icon 3 (4.2%) 0 (0.0%) 68 (95.8%)
16 Steatorrheaarrow icon 3 (14.3%) 0 (0.0%) 18 (85.7%)
17 cirrhosisarrow icon 2 (2.8%) 0 (0.0%) 69 (97.2%)
18 Hepatosplenomegalyarrow icon 2 (2.8%) 0 (0.0%) 69 (97.2%)
19 Pancreatitisarrow icon 2 (9.5%) 0 (0.0%) 19 (90.5%)
20 Childhood onsetarrow icon 1 (14.3%) 0 (0.0%) 6 (85.7%)
21 Cor pulmonalearrow icon 1 (14.3%) 0 (0.0%) 6 (85.7%)
22 Hepatomegalyarrow icon 1 (1.4%) 0 (0.0%) 70 (98.6%)
23 Nasal polypsarrow icon 1 (4.8%) 0 (0.0%) 20 (95.2%)

Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications

Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.